Right‑Heart Catheterization: Evidence‑Based Guidelines

Diagnostic Utility

• Right‑heart catheterization (RHC) is the gold‑standard method for diagnosing and assessing pulmonary hypertension and heart failure because it provides direct intracardiac pressure, cardiac output, and pulmonary vascular resistance measurements that cannot be reliably obtained by non‑invasive techniques. [European Respiratory Society] 1 [American College of Chest Physicians] 2

Core Hemodynamic Measurements

Pressure Values

• Mean pulmonary artery pressure (mPAP) normal range is 9–18 mmHg (systolic 15–30 mmHg, diastolic 4–12 mmHg). [European Society of Cardiology] 3
• Pulmonary artery wedge pressure (PAWP) is normally ≤15 mmHg and reflects left‑atrial pressure and left‑ventricular end‑diastolic pressure. [European Respiratory Society] 1

Cardiac Output

• Cardiac output is measured directly and accurately by thermodilution, in which a known volume of fluid at a known temperature is injected into the right atrium and the downstream temperature change is recorded. [American College of Chest Physicians] 2

Oxygen Saturation for Shunt Detection

• Blood samples obtained from the superior vena cava, inferior vena cava, and pulmonary artery are used to detect intracardiac shunts; a wedge‑position sample should have the same oxygen saturation as systemic blood, confirming accurate PAWP measurement. [European Respiratory Society] 1

Calculated Hemodynamic Parameters

• An elevated pulmonary vascular resistance (PVR > 3 Wood units) distinguishes precapillary from post‑capillary pulmonary hypertension. [European Respiratory Society] 4
• Transpulmonary gradient (TPG) normal ≤12 mmHg; a TPG > 12 mmHg indicates a “reactive” or out‑of‑proportion post‑capillary pulmonary hypertension. [European Society of Cardiology] 3

Definition and Classification of Pulmonary Hypertension

• Pulmonary hypertension (PH) is defined as a mean pulmonary artery pressure ≥25 mmHg at rest. [European Respiratory Society] 1 [European Society of Cardiology] 3
• Normal mean PAP is 14 ± 3 mmHg (upper limit 20 mmHg); values 21–24 mmHg are of uncertain significance. [European Society of Cardiology] 3

Hemodynamic Profiles

Prognostic Significance in Idiopathic PAH

• In the NIH Registry, higher mean PAP, higher right‑atrial pressure, and lower cardiac index were independently associated with reduced survival, forming the basis of a hemodynamic survival‑prediction model. [American College of Chest Physicians] 2

Assessment in Heart Failure

• Direct measurement of left‑ventricular end‑diastolic pressure is essential to avoid misclassifying patients with elevated PAWP when clinical risk factors for heart failure with preserved ejection fraction are absent; a low threshold for adding left‑heart catheterization is recommended in such patients. [European Respiratory Society] 5
• PAWP > 15 mmHg indicates left‑heart disease as the primary cause of PH. [European Respiratory Society] 1
• Elevated right‑atrial pressure together with reduced cardiac output identifies decompensated right‑ventricular failure. [American College of Chest Physicians] 2

Technical Considerations

• Zero referencing – The external pressure transducer must be zeroed at the mid‑thoracic line (midway between the anterior sternum and the bed) in a supine patient, approximating left‑atrial level. [European Respiratory Society] 5
• Timing of measurements – Pressures should be recorded at end‑expiration without breath‑holding; averaging over several respiratory cycles is acceptable except in dynamic hyperinflation. [European Respiratory Society] 1
• PAWP verification – Record the mean of three PAWP readings; confirm wedge‑position blood sample saturation matches systemic blood; avoid repeated balloon inflations/deflations in distal pulmonary arteries to reduce rupture risk. [European Respiratory Society] 4
• Waveform quality – Use high‑fidelity tracings that can be printed for detailed waveform analysis, improving detection of artifacts. [European Respiratory Society] 1

Measurement Variability

• In patients with pulmonary arterial hypertension, intra‑individual spontaneous variability of pulmonary artery pressure can reach up to 20 mmHg, with a mean coefficient of variation of 8 %, underscoring the need for multiple measurements and contextual interpretation. [American College of Chest Physicians] 2

Safety Profile

• When performed at expert centers, RHC has a morbidity rate of approximately 1.1 % and a mortality rate of 0.055 %. [European Respiratory Society] 5

Integration with Non‑Invasive Testing

• RHC should be undertaken after completion of non‑invasive investigations to answer specific residual questions and to avoid unnecessary invasive procedures; interpretation of invasive hemodynamics must be correlated with clinical findings and imaging, particularly echocardiography. [European Respiratory Society] 5

Pulmonary Hypertension Classification and Management

Definition and Diagnosis

• Pulmonary hypertension is defined as a mean pulmonary arterial pressure ≥25 mmHg at rest as assessed by right heart catheterization, according to the European Respiratory Society 6, 7, 8

Classification of Pulmonary Hypertension

Group 1: Pulmonary Arterial Hypertension (PAH)

• PAH is characterized by pre-capillary PH with pulmonary vascular resistance >3 Wood units and normal pulmonary artery wedge pressure ≤15 mmHg, as defined by the European Respiratory Society 6, 7
• The European Respiratory Society identifies subtypes of PAH, including idiopathic PAH 6, heritable PAH (BMPR2 and other mutations) 6, drug and toxin-induced PAH 6, 9, and associated PAH (connective tissue disease, HIV infection, portal hypertension, congenital heart disease, schistosomiasis) 6, 8

Group 2: PH Due to Left Heart Disease

• The European Respiratory Society defines PH due to left heart disease as PAPm ≥25 mmHg with PAWP >15 mmHg 8, 10
• This group includes left ventricular systolic dysfunction 10, left ventricular diastolic dysfunction 10, valvular disease 10, 9, and congenital/acquired left heart inflow/outflow tract obstruction 10

Group 3: PH Due to Lung Diseases and/or Hypoxia

• The European Respiratory Society identifies chronic obstructive pulmonary disease 6, 11, interstitial lung disease 6, 11, sleep-disordered breathing 6, 11, alveolar hypoventilation disorders 6, 11, and chronic exposure to high altitude 6, 11 as causes of PH due to lung diseases and/or hypoxia

Group 4: Chronic Thromboembolic PH (CTEPH)

• CTEPH is characterized by organized thrombi obstructing pulmonary arteries, as defined by the European Respiratory Society 6, 12
• The European Respiratory Society identifies chronic thromboembolic pulmonary hypertension 12 and other pulmonary artery obstructions (angiosarcoma, other intravascular tumors, arteritis, congenital pulmonary artery stenoses, parasites) 12 as subtypes of CTEPH

Group 5: PH with Unclear and/or Multifactorial Mechanisms

• The European Respiratory Society identifies hematological disorders (chronic hemolytic anemia, myeloproliferative disorders, splenectomy) 6, 13, systemic disorders (sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis, neurofibromatosis) 6, 13, metabolic disorders (glycogen storage disease, Gaucher disease, thyroid disorders) 6, 13, and others (pulmonary tumoral thrombotic microangiopathy, fibrosing mediastinitis, chronic renal failure) 6, 13 as causes of PH with unclear and/or multifactorial mechanisms

Diagnosing Pulmonary Hypertension

Introduction to Diagnostic Methods

• The American Thoracic Society and European Respiratory Society recommend right heart catheterization (RHC) as the gold standard for diagnosing pulmonary hypertension, as it provides direct and accurate measurements that cannot be reliably obtained through non-invasive methods alone 14, 15

Importance of Right Heart Catheterization

• RHC is essential to confirm the diagnosis of pulmonary hypertension because it provides critical diagnostic parameters, including mean pulmonary arterial pressure, pulmonary artery wedge pressure, pulmonary vascular resistance, right atrial pressure, and cardiac output/index, which are necessary for risk stratification and prognosis 14
• The European Society of Cardiology recommends that RHC be performed in expert centers with meticulous attention to technical detail to obtain clinically useful information and minimize risk 15

Technical Requirements for RHC

• Proper zero referencing, sequential pressure measurements, and careful balloon technique are crucial for accurate and safe RHC, as recommended by the European Heart Journal 15

Limitations of Echocardiography

• The European Respiratory Journal notes that echocardiography alone is insufficient to support treatment decisions for pulmonary hypertension, as Doppler-derived pressure estimates may be inaccurate in individual patients, and tricuspid regurgitation velocity can be significantly underestimated in severe tricuspid regurgitation 16, 17

Diagnostic Algorithm

• When echocardiography shows high probability of pulmonary hypertension, further investigation, including RHC, is recommended by the European Respiratory Journal, and for intermediate probability with risk factors or associated conditions, RHC should be considered 18, 19

Additional Diagnostic Value of RHC

• RHC provides exclusion of alternative diagnoses, assessment of right heart dysfunction, vasoreactivity testing, and risk stratification, which are essential for guiding treatment decisions, as noted by the American College of Chest Physicians and the European Heart Journal 14, 15

Clinical Assessment and Management of Pulmonary Hypertension in Young Males

Symptoms

Physical Examination Findings

Etiology‑Specific Physical Clues

Non‑Invasive Diagnostic Tests

Management Precautions

Prognostic Indicators

All cited facts are derived from the European Respiratory Society recommendations (European Respiratory Journal, 2015) 20.

Right‑Heart Catheterization in Pulmonary Hypertension – Evidence‑Based Recommendations

1. Indications and Procedural Requirements

• Right‑heart catheterization (RHC) is mandatory to confirm pulmonary hypertension (PH), classify its hemodynamic type, assess disease severity, and guide all treatment decisions; it must be performed before any PAH‑specific therapy. 21
• RHC is the gold‑standard diagnostic test and is required in every patient with suspected PH; echocardiography alone is insufficient and may be inaccurate. 21, 22
• RHC should be performed only at expert centers because of its technical complexity; reported complication rates are morbidity ≈ 1.1 % and mortality ≈ 0.055 %. 23

2. Core Hemodynamic Measurements Obtained by RHC

3. Vasoreactivity Testing

• Indicated only for patients with idiopathic, heritable, or drug‑induced PAH; never for other PH groups. Testing must be performed at expert centers by physicians experienced in pulmonary vascular disease. 24
• Nitric oxide is the preferred vasodilator; intravenous epoprostenol or adenosine are acceptable alternatives. 24
• A positive acute response is defined as a ≥10 mmHg fall in mPAP to an absolute value ≤40 mmHg with unchanged or increased cardiac output. 24
• Approximately 10 % of idiopathic PAH patients exhibit a positive response and are candidates for high‑dose calcium‑channel blocker (CCB) therapy. 24
• CCBs must not be used empirically without documented vasoreactivity, as they can be harmful in non‑responders. 24

4. How RHC Guides Therapeutic Decision‑Making

• Hemodynamic profiles derived from RHC determine eligibility for specific PAH drug classes (endothelin‑receptor antagonists, prostacyclin analogues, phosphodiesterase‑5 inhibitors) based on functional class and severity. 24
• Patients in functional class III who are non‑vasoreactive or who have failed CCB therapy should be considered for advanced PAH therapies. 24
• Patients with suspected chronic thromboembolic PH (CTEPH) should be referred to experienced centers for pulmonary thrombo‑endarterectomy evaluation when RHC shows precapillary PH with organized thrombi. 24
• Patients with NYHA/WHO functional class III‑IV symptoms should be evaluated for lung or heart‑lung transplantation; bilateral lung transplantation is the preferred surgical option. 24

5. Prognostic and Risk‑Stratification Value

• Higher mPAP, higher RAP, and lower cardiac index independently predict reduced survival in the NIH Registry cohort. 21, 22
• These hemodynamic variables form the core of survival‑prediction models that guide intensity of therapy. 21, 22

6. Technical Considerations and Measurement Limitations

• Single pressure readings can vary spontaneously by up to ±20 mmHg (coefficient of variation ≈ 8 %); therefore, multiple measurements and averaging are essential. 21, 22
• RHC measurements are obtained in the resting, supine state and may not reflect hemodynamics during upright posture, physical activity, or sleep. 21, 22
• Despite these limitations, RHC remains the indispensable gold‑standard for PH diagnosis and management. 21, 22

7. Additional Diagnostic Contributions

• RHC can exclude alternative diagnoses such as intracardiac or extracardiac shunts and unsuspected left‑heart disease that are not apparent on echocardiography. 21

Pulmonary Hypertension Secondary to Left‑Heart Disease (Group 2 PH)

Epidemiology

Hemodynamic Definition

Pathophysiology

Clinical Presentation

Prognostic Implications

Management Recommendations

Classification and Etiology of Pulmonary Hypertension

Overview of Pulmonary Hypertension Classification

• Pulmonary hypertension (PH) is divided into five clinical groups based on underlying pathophysiology, hemodynamics, and therapeutic approach, with left‑heart disease (Group 2) and chronic lung disease (Group 3) being the most common causes, while pulmonary arterial hypertension (Group 1) is a rarer subset that requires disease‑specific therapy. [28][29]

Hemodynamic Definitions Used Across All Groups

• A mean pulmonary artery pressure (mPAP) ≥ 25 mmHg defines PH; a pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg identifies pre‑capillary disease, whereas PAWP > 15 mmHg indicates post‑capillary PH. Pulmonary vascular resistance (PVR) > 3 Wood units confirms pre‑capillary pulmonary arterial hypertension. [28][29]

Group 1 – Pulmonary Arterial Hypertension (PAH)

Core Hemodynamic Criteria

• PAH is a pre‑capillary PH characterized by mPAP ≥ 25 mmHg, PAWP ≤ 15 mmHg, and PVR > 3 Wood units. 29

Idiopathic and Heritable Forms

• Idiopathic PAH occurs without an identifiable trigger and shows a higher prevalence in women. [28][30]
• Heritable PAH is most often linked to BMPR2 mutations and follows an autosomal‑dominant pattern with incomplete penetrance. [28][29]30

Drug‑ and Toxin‑Induced PAH

• Definite causative agents include appetite‑suppressing anorexigens and the tyrosine‑kinase inhibitor dasatinib. [28][29]
• Discontinuation of the offending drug can lead to clinical and hemodynamic recovery. 28

Associated Conditions (Associated PAH)

• Connective‑tissue diseases—especially systemic sclerosis—carry the highest risk and worst prognosis for PAH. [28][29]30
• Congenital heart diseases with systemic‑to‑pulmonary shunts (e.g., atrial or ventricular septal defects) are recognized contributors. [28][29]
• Portal hypertension secondary to chronic liver disease is an established association. [28][29]30
• HIV infection is linked to the development of PAH. [28][29]30
• Schistosomiasis infection can precipitate PAH. 29
• Hemoglobinopathies such as sickle‑cell disease and other chronic hemolytic anemias are associated with PAH. [28][29]
• Chronic myeloproliferative disorders and post‑splenectomy states are recognized risk factors. [28][29]

Pulmonary Veno‑Occlusive Disease (PVOD) & Pulmonary Capillary Hemangiomatosis (PCH)

• PVOD and PCH are distinct entities marked by prominent venous or capillary involvement and may be idiopathic, heritable (EIF2AK4 mutations), or secondary to drugs, radiation, connective‑tissue disease, or HIV infection. [28][29]

Group 2 – PH Due to Left‑Heart Disease

• This is the most prevalent PH phenotype, affecting up to 60 % of patients with severe left‑ventricular systolic dysfunction and up to 70 % of those with heart failure with preserved ejection fraction. 29

Hemodynamic Profile

• PH in left‑heart disease is defined by mPAP ≥ 25 mmHg together with PAWP > 15 mmHg, distinguishing it from pre‑capillary PH. 29

Principal Etiologies

• Left‑ventricular systolic dysfunction of any origin. 29
• Left‑ventricular diastolic dysfunction, commonly secondary to chronic systemic hypertension leading to LV hypertrophy. 29
• Severe symptomatic mitral valve disease (virtually all patients) and up to 65 % of patients with symptomatic aortic stenosis develop PH. 29
• Congenital or acquired obstruction of left‑heart inflow/outflow tracts and pulmonary vein stenosis. 29

Pathophysiologic Subtypes

• Isolated post‑capillary PH (transpulmonary gradient ≤ 12 mmHg).
• Combined pre‑ and post‑capillary PH (transpulmonary gradient > 12 mmHg), indicating a “reactive” or “out‑of‑proportion” component due to superimposed pulmonary vascular remodeling. 29

Group 3 – PH Associated with Lung Diseases and/or Hypoxemia

• PH secondary to chronic lung disease is common, though severe elevation (mPAP ≥ 35 mmHg) is relatively rare.

Key Pulmonary Causes

• Chronic obstructive pulmonary disease (COPD) is the most frequently encountered lung disease linked to PH. 29
• Interstitial lung disease, including idiopathic pulmonary fibrosis, contributes to PH development. 29
• Sleep‑disordered breathing (obstructive sleep apnea, obesity‑hypoventilation syndrome) is an established risk factor. 29
• Alveolar hypoventilation disorders, chronic high‑altitude exposure, and developmental lung abnormalities are also implicated. 29

Group 4 – Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

• CTEPH results from organized thrombotic material obstructing pulmonary arteries, producing a pre‑capillary hemodynamic pattern. 29

Specific Etiologies

• Obstruction of proximal pulmonary arteries by organized thrombi. [28][29]
• Obstruction of distal pulmonary arteries by similar thrombotic material. [28][29]
• Non‑thrombotic emboli from tumors, parasites (e.g., hydatid disease), or foreign material. [28][29]
• Intravascular tumors such as angiosarcoma. 29
• Pulmonary artery arteritis. 29
• Congenital pulmonary artery stenoses. 29

Group 5 – PH with Unclear or Multifactorial Mechanisms

Hematologic Contributors

• Chronic hemolytic anemia, myeloproliferative disorders, and post‑splenectomy states are associated with PH. 29

Systemic Disorders

• Sarcoidosis, pulmonary Langerhans cell histiocytosis, lymphangioleiomyomatosis, and neurofibromatosis have been linked to PH. [28][29]

Metabolic Disorders

• Glycogen storage diseases, Gaucher disease, and various thyroid disorders are recognized as rare PH precipitants. [28][29]

Miscellaneous Causes

• Pulmonary tumoral thrombotic microangiopathy, fibrosing mediastinitis causing vascular compression, chronic renal failure (with or without dialysis), and segmental pulmonary hypertension are additional, less common mechanisms. [28][29]

Classification and Etiology of Pulmonary Hypertension

Overview

• Pulmonary hypertension (PH) is divided into five mechanistic groups; left‑heart disease (Group 2) and chronic lung disease (Group 3) are the most prevalent, while pulmonary arterial hypertension (Group 1) is less common and requires disease‑specific therapy. 31

Hemodynamic Definition

• PH is diagnosed when the mean pulmonary artery pressure (mPAP) is ≥ 25 mm Hg at rest as measured by right‑heart catheterisation. 31, 32

Group 1 – Pulmonary Arterial Hypertension (PAH)

Diagnostic Hemodynamics

• PAH is defined by mPAP ≥ 25 mm Hg, pulmonary artery wedge pressure (PAWP) ≤ 15 mm Hg, and pulmonary vascular resistance (PVR) > 3 Wood units. 31

Genetic Contributions

• Mutations in ALK1 and endoglin genes are linked to hereditary hemorrhagic telangiectasia‑associated PAH. 32

Drug‑ and Toxin‑Induced PAH

• Established causative agents include appetite suppressants (aminorex, fenfluramine, dexfenfluramine) and the tyrosine‑kinase inhibitor dasatinib. 31

Congenital Heart Disease

• Systemic‑to‑pulmonary shunts (e.g., atrial or ventricular septal defects, patent ductus arteriosus) can evolve to Eisenmenger syndrome when pulmonary vascular resistance surpasses systemic resistance. 31

Liver‑Related PH

• Portal hypertension secondary to chronic liver disease raises PAH risk, with incidence increasing alongside worsening hepatic function. 31

Infectious and Parasitic Causes

• HIV infection is associated with PAH in roughly 0.5 % of infected individuals, independent of CD4 count but related to infection duration. 31
• Schistosomiasis is a major PAH trigger in endemic regions. 31

Hematologic and Myeloproliferative Associations

• Chronic hemolytic anemias (e.g., sickle cell disease, thalassemia, hereditary spherocytosis) and myeloproliferative disorders or post‑splenectomy states are linked to PAH. 31

Pulmonary Veno‑Occlusive Disease & Pulmonary Capillary Hemangiomatosis

• PVOD and PCH may be idiopathic, heritable (EIF2AK4 mutations), or secondary to drugs, radiation, connective‑tissue disease, or HIV infection. 31

Group 2 – PH Due to Left‑Heart Disease

Prevalence

• Up to 60 % of patients with severe left‑ventricular systolic dysfunction and up to 70 % of those with heart‑failure with preserved ejection fraction develop PH. 31

Hemodynamic Criteria

• Defined by mPAP ≥ 25 mm Hg together with PAWP > 15 mm Hg, indicating a post‑capillary pattern. 31

Principal Etiologies

• Left‑ventricular systolic dysfunction of any origin. 31
• Left‑ventricular diastolic dysfunction, frequently secondary to chronic systemic hypertension causing LV hypertrophy and impaired relaxation. 31
• Severe symptomatic mitral valve disease (virtually all patients) and up to 65 % of symptomatic aortic stenosis patients develop PH. 31
• Congenital or acquired obstruction of left‑heart inflow/outflow tracts and pulmonary‑vein stenosis. 31

Group 3 – PH Due to Lung Diseases and/or Hypoxia

Key Pulmonary Contributors

• Chronic obstructive pulmonary disease (COPD) is the most common lung disease associated with PH. 31
• Interstitial lung disease, including idiopathic pulmonary fibrosis, is linked to PH. 31
• Sleep‑disordered breathing (obstructive sleep apnea, obesity‑hypoventilation syndrome) contributes to PH development. 31
• Alveolar hypoventilation disorders, chronic exposure to high altitude, and developmental lung abnormalities are additional recognized causes. 31

Group 4 – Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Pathophysiology

• CTEPH arises from organized thrombotic material obstructing pulmonary arteries, producing a pre‑capillary haemodynamic profile. 31

Non‑Thrombotic Obstructions

• Rare causes include intravascular tumours (e.g., angiosarcoma), pulmonary‑artery arteritis, congenital pulmonary‑artery stenoses, and parasitic infections such as hydatid disease. 31

Group 5 – PH with Unclear or Multifactorial Mechanisms

Hematologic Disorders

• Chronic hemolytic anemia, myeloproliferative disorders, and post‑splenectomy states may lead to PH. 31

Systemic Disorders

• Conditions such as sarcoidosis, pulmonary Langerhans‑cell histiocytosis, lymphangioleiomyomatosis, and neurofibromatosis are implicated. 31

Metabolic Disorders

• Glycogen‑storage diseases, Gaucher disease, and various thyroid disorders are associated with PH. 31

Miscellaneous Causes

• Pulmonary tumoral thrombotic microangiopathy, fibrosing mediastinitis causing vascular compression, and chronic renal failure (with or without dialysis) can precipitate PH. 31